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1. Introduction 
Recent advances in understanding of inflammatory bowel diseases (IBD) pathogenesis, 
despite the questions remaining still unanswered, have led to improved approaches in 
ulcerative colitis (UC) and Crohn`s disease (CD) treatment. In depth investigation of 
immunopathology of IBD and mucosal inflammation enabled the identification of new 
strategies for drug targeting, new points of therapeutic attack, cytokine based therapies and 
new therapeutic agents. Further understanding of the genetic background of this disease 
will enable discovery of potential gene therapy target molecules related to chronic intestinal 
inflammation, like new therapeutic targets in IBD. 
There is a vast body of information and research associated with current medical treatments, 
their undesirable effects and limited efficacy. Different drug delivery strategies were 
employed to overcome limited performance of conventional IBD therapy and many more 
will be designed to enable safe and efficacious delivery of newly developed therapeutic 
agents. Both diseases, UC and CD involve different parts of the gastrointestinal (GI) system. 
CD may involve any part of the GI tract, although most commonly the terminal ileum and 
colon, while UC usually involves only the colon and always extends proximally from the 
rectum. T helper 1 (Th1) stimulated immune dysregulation is characteristic for CD while T 
helper 2 (Th2) stimulated immune dysregulation causes inflammatory mediatory imbalance 
characteristic for UC (Bouma & Strober, 2003; Hedley, 2000; Sands, 2007; Sellin, 2005). 
Treatment of UC and CD varies depending on subtype and severity, but significant overlap 
is seen.  The most common therapeutic agents for IBD, aminosalycilates and corticosteroids, 
have been incorporated into different dosage forms and drug delivery systems (DDS) in 
order to accomplish successful topical delivery of these agents at the site of inflammation (in 
CD - terminal ileum, or colon, the site of inflammation for both subtypes) (Green et al., 2002; 
Haddish-Berhane et al., 2007; Sands, 2007). The most critical step in the development of a 
reliable DDS for IBD treatment is to achieve improved localization and controlled release of 
the active substance at the site of inflammation, minimizing the premature release and 
subsequent absorption in the blood stream.  However, the main disadvantage of today’s 
therapy and DDS for management of IBD is the inability to target the drug directly to the 
site of action (inflammation) and/or to maintain high local concentration. In addition to 
poor localization extensive metabolism at the level of the epithelial cells of the intestinal wall 
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(ex. hydroxylation of budesonide by cytochrome P450 isoenzyme CYP3A4 in hepatocytes 
and epithelial cells) might further impair local concentration required for improved drug 
efficacy (Fedorak & Bistritz, 2005; Klotz & Schwab, 2005). 
2. Conventional design strategies for GI targeting 
The efficacy of the treatment of IBD depends on the functionality of the strategy for the 
delivery of therapeutic concentrations of the drug substance at the site of inflammation. In 
addition, minimizing the intestinal absorption using different formulation design 
approaches will improve the safety and reduce the adverse effects of the treatments. Various 
chemical modifications and formulation technologies based on the intestinal physiology 
(motility, intraluminal pH, and intestinal transit times) as well as distribution of IBD in the 
GI tract have been developed in order to improve the efficacy and precision of drug release 
to the affected areas.   
These conventional approaches are mainly focused to targeting a particular site in the GI 
tract and delivery of prodrugs, colonic microflora activated systems, pH dependent and 
time dependent systems in a form of single or multiunit dosage forms (Gazzaniga et al., 
2006; Ishibashi et al., 1998). Delivery strategies and release mechanisms employed in these 
dosage forms rely on the enzymatic activity of the GI microflora, pH difference between 
different parts of the GI tract, GI transit time and increased luminal pressure in the colon 
due to strong peristaltic waves (Leopold, 2001). The conditions in the complex and 
dynamic GI tract environment are the source of variability of drug release, absorption and 
patient response even if healthy individuals are concerned. Moreover, due to the 
pathological changes in response to the IBD, factors like GI tract pH, motility, transit time 
and microflora activity will become the source of increased variability in the response  
and effectiveness of different formulations for treatment of the GI diseases. Before 
mentioned factors and variables suggest that these design approaches might suffer from 
limited efficacy in concentrating the active substance at the site of inflammation, 
preventing drug absorption and systemic exposure to these agents. Moreover, if single 
unit dosage forms are used, their residence time in GI tract will be under constant threat 
of persistent diarrhea in IBD patients (Bourgeois, 2005; Chourasia & Jain, 2003; Roy & 
Shahiwala, 2009). 
Today it is widely accepted that the delivery of the active substance influences clinical 
efficacy of the drug product. Based upon this view, clinical studies for the efficacy and 
safety of different conventional marketed DDS describing the site of drug release, drug 
release rate, subsequent absorption from the GI tract, systemic absorption and local 
concentration of the anti-inflammatory agents are the baseline for rational approach in 
prescribing different doses and dosage forms for IBD, once the location and the type  
of the disease are known. Due to the clinical efficacy studies valuable information for the 
usefulness of different dosage forms for the treatment of mild or moderate disease, 
induction or maintaining remission etc. related to the disease pattern and drug 
disposition are available (Clemett & Markham, 2000; Prakash, 1999). Moreover, there  
is increasing number of papers trying to investigate and explain variation in luminal pH 
in UC and CD patients, mucosal flora profiles for UC and CD which will further improve 
the understanding of the effect of these variables on the drug release pattern and 
disposition as well as clinical efficacy of different drug products, but will also help the 
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profiling of different phenotypes of IBD (Friend, 2005; Haddish-Berhane et al., 2007; 
Nugent et al., 2001). 
2.1 Prodrug approach 
The rationale behind the utilization of a prodrug approach for drug targeting in IBD is 
multilateral. Nevertheless, the first 5-ASA prodrug was developed to deliver sulfonamide 
specifically to the colon, later it was realized that sulfasalazine (sulfapyridyne-azo 
linkage-5ASA) is efficient for UC treatment as it can successfully perform colon specific 
delivery of 5-ASA after oral administration, at the same time it can reduce the absorption 
in the upper intestines due to increased hydrophylicity and/or molecular size (Friend, 
2005; Sands, 2007). Azo prodrug approach for colon targeting will improve local 
concentration of the active substance at the site of therapeutic action, resulting with 
increased efficacy and fewer side effects of the therapy (Bourgeois, 2005; Oz & Ebersole, 
2008; Sands, 2000) . These cannot be linearly applied to all azo conjugates as the side 
effects may originate from the carrier molecule or degradation products also released 
during the azo bond cleavage. 
The trigger that releases the active substances from their azo-prodrugs is the colon micoflora 
enzymatic activity. Contrary to the small intestine (104 CFU/ml mainly gram positive 
facultative bacteria), colonic flora is of much higher order (1011–1012 CFU/ml) and is mainly 
consisted of an anaerobic bacteria (Mcconnell et al., 2008; Sinha & Kumria, 2001).  For the 
fermentation of undigested substrates in the small intestine like disaccharides, 
polysaccharides, mucopolysaccharides, and fulfillment of microflora energy demands, these 
commensal bacteria produce different types of enzymes like azoreductase, β-galactosidase, 
ǃ-xylosidase, nitroreductase, glycosidase, deaminase etc. (Bourgeois, 2005; Han & Amidon, 
2000; Oz & Ebersole, 2008; Yang, 2008). Most of these anaerobic bacteria are capable of 
reducing azo linkages, thus releasing the active drug from the azo product.  Beside azo 
prodrugs based on azo linkage of the drug with different carriers, other systems for colon 
drug targeting based on colonic microflora activity are also developed. The rationale behind 
glucuronide conjugates development as colon targeting systems is based on the β-
glucuronidase activity in the lower GI tract; cyclodextrin (CyD) conjugates are based on 
poor digestion of the complex through the GI tract except in the colon by the colonic 
microflora; the drug is released from dextran-drug conjugates due to dextranase activity in 
the region of caecum and colon; amino acid conjugates are probably hydrolyzed by the 
microbial flora activity at the location of the caecum and colon, etc. (Bourgeois, 2005; 
Chourasia & Jain, 2003). Examples of the prodrug products available on the market and of 
the prodrug systems still under research are presented in Table 1.  
The functionality of these delivery systems is directly influenced by i). the stability of the 
conjugate in the upper GI tract, ii). colon specific complex degradation and iii). toxicity of 
the carrier or the cleavage products. Their capacity when applied for targeting in IBD 
treatment is to release and increase localization and concentration of the drug substance at 
the specific site in GI tract (site specific delivery). Commercially available 5-ASA conjugates 
are not able to completely prevent prodrug hydrolysis and 5-ASA absorption in the upper 
GI tract. Although the approaches presented in the literature using different polymer 
carriers might probably overcome this weakness, apparently creating a balance among the 
resilience against hydrolysis in the upper GI tract and required drug release rate in colon is 
not an easy task. 
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Conjugates Drug  Carrier molecule  Release mechanism  Source  
Azo prodrugs  
Sulfasalazine  5-ASA Sulfapyridine  Enzymatic cleavage 
(azoreduction)  of the 
azo-bond by azo-
reductases in the colon 
 
Marketed 
product 
Balsalazide 5-ASA 4-aminobenzoyl-ǃ-
alanine 
Marketed 
product 
Olsalazine 
(disodium 
azodisalicylate) 
5-ASA One molecule of 5-
ASA is used as a 
carrier for the other  
Marketed 
product 
Non-absorbable 
polymer-drug 
azo conjugate 
5-ASA Sulphanilamidoethyl
-ene polymer 
(Brown et 
al., 1983) 
Water soluble 
polymer-drug  
azo conjugate 
5-ASA N-(-hydroxypropyl) 
methacrylamide 
copolymer 
(Kopecek, 
1990) 
 
Bioadhesive 
polymer-drug  
azo conjugate 
5-ASA N-(2-hydroxypropyl) 
methacrylamide 
copolymers with 
bioadhesive  
moiety 
(fucosylamine)  
(Kopecek  
et al., 1992) 
Amino-acid conjugates 
Drug-amino acid 
conjugate 
5-ASA Glycine  Enzymatic hydrolysis 
of the amide bond  
by the GI 
microorganisms  
in the caecum and 
colon 
(Jung et al., 
1998) 
Glycoside and glucuronide conjugates 
Drug-glycoside 
conjugate 
(coupling 
through 
β−glycosidic 
bond) 
Prednisolone 
or  
Dexametha- 
sone 
β-D-glucoside฀ Enzymatic hydrolysis - 
cleavage of the polar 
moiety by bacterial 
glycosidases in the 
colon 
(Friend & 
Chang, 
1985)  
Drug-
glycoronide 
conjugate 
Budesonide β-D-glucuronide Enzymatic  
hydrolysis - 
Deglucuronidation of 
the drug – glucuronic 
acid prodrug  by the 
β฀−glucuronidase 
secreted by GI  
bacteria in the  
colon 
(Friend, 
1991; 
Nolen et 
al., 1995)  
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Cyclodextrin (CyD) conjugates 
Prednisolone 
Succinate-CyD 
Ester Conjugate 
Prednisolone 
 
α-CyD฀ Enzymatic hydrolysis - 
Bacterial enzymatic 
degradation of CyD 
rings to small 
saccharides followed by 
ester hydrolysis in the 
lower parts of GI tract 
(Yano et 
al., 2001) 
Polysaccharide  conjugates 
Dextran 
conjugate 
5-ASA Oxidised dextran 
(dialdehyde dextran) 
coupled to alpha 
NH2 groups from 5-
ASA to form imine 
bonds which are 
further reduced to 
secondary amine 
bonds to improve 
stability in water  
Enzymatic hydrolysis 
of the amine complex 
by deaminases and the 
dextrane glycoside 
bonds in the distal 
ileum and proximal 
colon by dextranases  
to oligomers  
which are further  
split by colonic 
esterases  
(Ahmad et 
al., 2006) 
Dendrimer conjugates
Hydrophylic 
polyamidoamine 
dendrimer 
(PAMAM) 
5-ASA PAMAM (drug is 
bound to the 
polymer via spacers 
containing azo 
bonds: p-
aminobenzoic acid 
spacer and p-
aminohippuric acid 
spacer) 
Enzymatic cleavage  of 
the azo-bond by 
colonic azo-reductases 
(Wiwattana
patapee et 
al., 2003) 
Table 1. Conjugates for colon drug targeting 
2.2 pH, time and microbiologically dependent systems for colon targeting 
Drug delivery approaches for pH and time dependent systems currently on the market 
are based on polymer coating or matrix technology for single or multiple unit dosage 
forms. Eudragit S coated 5-ASA tablets (Asacol®) and Eudragit L coated 5-ASA tablets 
(Salofalk®, Claversal®, Mesazal®, Calitoflak®) represent purely pH dependent delayed 
release systems  which release the active substance upon the dissolution of the polymer 
coating, generally at pH 7 or pH 6 for Eudragit S and Eudragit L coating, respectively 
(Klotz & Schwab, 2005; Leopold, 2001; Wilding et al., 2000). Entocort® is designed as 
Eudragit L100-55 coated budesonide/ethylcellulose beads in gelatin capsule in order to 
delay the release of the active substance till pH 5.5 and further sustain the drug release 
through GI tract due to the presence of ethylcellulose (Fedorak & Bistritz, 2005; Friend, 
2005; Klotz & Schwab, 2005). The coating of combined Eudragit enterosoluble and 
swelling polymers (Eudragit L/S/RL an RS) in Budenofalk microgranules is supposed to 
delay the release until pH 6.4.  It is assumed that multiunit coated beads will provide 
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more uniform transit and distribution through the GI tract and accordingly more uniform 
drug release as they are less subjected to the differences in the transit time due to the 
environmental changes. Accordingly, the exposition of the dosage forms to an acidic 
environment due to the differences in the gastric emptying process for pellets and tablets 
might be different.  Pellets are continuously emptied from the stomach (unless settled at 
the greater curvature or float because of the high or low density, respectively) during the 
digestive period, and non-desintegrating tablets, like enteric coated tablets, are emptied 
during the interdigestive period. The description of the drug release site according to the 
solubility of the enterosolvent coating is a valuable orientation point, but at the same time 
very general as it can be only applied in ideal circumstances and is subjected to number of 
inter-, intra-individual variables as well as different disease factors. However, it might be 
expected that patients with UC will have the greatest benefit as by design pH dependent 
dosage forms will deliver most of the dose in the distal ileum and colon.  Latest published 
research data on small bowel pH in patients with ileal CD (3 patients with ileal CD, 8 
patients with operated ileal CD and 4 normal controls) point that small bowel pH was 
similar to the control group and sufficiently high to allow the dissolution of enterosolvent 
delayed release dosage forms coated with polymer that requires pH less than 7 to be 
dissolved (ex. Eudragit L) (Nugent et al., 2000). As these systems usually need at least 30 
minutes (max. 1 hour) to complete the dissolution in vitro it seems that the drug will be 
released during the transit through the small bowel towards the colon. Another study that 
measured the luminal pH and mean transit time in patients with mild to moderate UC 
clearly state that more than 50% of examined patients (10 males, 4 with extensive and 6 
with distal colitis) failed to achieve the sustained pH level needed for dissolution of some 
delayed release 5-ASA preparations (proximal, distal small bowel pH as well as right and 
left colon pH were measured). A different study confirmed that colonic pH is lower in 
patients with mild to moderate UC compared to the control group, but small bowel pH 
was not significantly changed compared to the controls (Friend, 2005; Oliveira, L. & 
Cohen, 2011). Opposite findings, from confirmed efficacy to incomplete drug release, are 
also found through the reports from clinical studies in the literature. As pH dependent 
systems are widely used in today’s practice careful and individual approach in 
prescribing of the delayed release systems for IBD would benefit the patient.  
Time based delivery systems release the drug in a sustained manner as they pass down the 
GI tract. Pentasa® is based on ethylcellulose coated beads that release 5-ASA slowly and 
continuously throughout the small bowel and colon in a time-dependent manner (Klotz & 
Schwab, 2005; Larouche, 1995; Wilding et al., 2000). Scintigraphic evaluation of the 
disposition, dispersion and movement of the Pentasa® microgranules through the GI tract 
(app. 1 mm in diameter) point that the particles showed fluid like properties in a fasted 
stomach, rapid exponential emptying in a progressive manner over 30-60 min period with 
no signs of delay. Colon arrival was observed within 4-6 hours on average followed by 
subsequent wide distribution of the beads through the colon. Accumulation of time 
controlled system in the ileo-caecal junction might present serious problem and should be 
carefully avoided by stimulating the colonic activity and gastrocolonic responce with a 
carefully scheduled light meal (Adkin et al., 1993; Price et al., 1993; Wilding et al., 2000). If 
the release of 5-ASA is successfully postponed or minimized by the presence of a 
ethylcellulose polymeric membrane till reaching the lower parts of the GI tract, this type of 
dosage form due to its wide multiunit distribution at the site of inflammation would be 
beneficial as the release is expected in a sustained manner through the entire colon. 
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Compared to pH dependent single unit dosage forms that release the drug in a short period 
after the dissolution of the coating,  multiple dose units spread all over the region of interest 
and release the drug in a sustained manner at the site of action. 
pH and time dependent systems were developed in order to combine delayed dissolution 
and sustained diffusion through swellable or non-swellable coatings or matrices. Apriso® is 
formulated as enteric coated microgranules with delayed release starting at pH 6.0 and 
polymer matrix core which will provide extended release of the active substance and deliver 
the drug continuously from the small bowel through the colon (Brunner  et al., 2003; 
Oliveira, L. & Cohen, 2011; Sandborn et al., 2010).  
Time dependent delivery systems like TIME CLOCK™ and Pulsincap™ are developed as 
colon drug delivery systems  based on the observation that the small intestinal transit time 
doesn’t exceed a mean of 3-4 hours (Bourgeois, 2005; Chourasia & Jain, 2003; Gazzaniga et al., 
2008). These systems usually show burst drug release after the lag time,  mainly due to the 
superdisintegrants and highly swellable agents which act upon the dissolution and 
permeability of the protective coating. TIME-CLOCK™ system, proposed by Pozzi et al. (Pozzi 
et al., 1994) is composed of tablet core containing the drug and bulking agents like lactose, 
polyvinyl pyrrolidone, corn starch and lubricant magnesium stearate, coated with 
hydrophobic dispersion of carnauba wax, bees’ wax, polyoxyethylene sorbitan monooleate 
and hydroxypropyl methylcellulose in water.  Drug release is not dependent to normal 
physiological conditions, pH, digestive state and anatomical position. The lag time can be 
modulated by altering the thickness of the coating. Pulsincap™ system consists of water 
insoluble capsule containing the formulation closed at the open end with a swellable hydrogel 
plug. Lag time is controlled by the type, dimensions and position of the plug and rapid drug 
release at particular site in GI tract is ensured by incorporation of disintegrants or effervescent 
agents. Pulsatile pH and time dependent multiple unit dosage forms composed of 
enterosolvent outer layer and a second membrane of water insoluble and enteric polymers are 
also suitable for colon drug targeting. OROS-CT™   system can be a single osmotic unit or may 
incorporate as many as 5-6 push-pull units, each 4 mm in diameter, encapsulated within a 
hard gelatin capsule (Leopold, 2001; Verma et al., 2000, 2002). Because of its drug-impermeable 
enteric coating, the release from each push-pull unit is prevented and delayed until higher pH 
values. When the acid resistant coating dissolves, water enters the unit, causing the osmotic 
push compartment to swell. Drug gel is forced out through the orifice due to the swelling 
effect and increased osmotic pressure in the push compartment at a rate precisely controlled 
by the rate of water transport through the semipermeable membrane. For treating ulcerative 
colitis, each push pull unit is designed with a 3-4 hours post gastric delay to prevent drug 
delivery in the small intestine. OROS-CT™ units can maintain a constant release rate for up to 
24 hours in the colon or can deliver drug over a period as short as four hours. 
Except the previously presented examples, approaches based on modification and 
combination of two or more conventional designs in order to improve the delivery and site 
specificity in the GI tract are presented through literature. Sinha and Kumria developed 
conventional enteric/coated time dependent single unit dosage form for colon specific 
delivery of water insoluble drugs or slightly soluble drugs (Sinha & Kumria, 2002). Time 
dependent delivery was achieved using xanthan gum, guar gum, chitosan and Eudragit E as 
binders. The most successful in sustaining the drug release in the upper GI tract was 
chitosan. Moreover, application of chitosan for site specific targeting of less soluble 
substances was favorable as the release was retarded only till microbial degradation or 
polymer solubilization took place in the colon. Another variation of pH and time dependent 
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single unit system for colonic delivery was published by Ishibashi et al (Ishibashi et al., 
1998). Drug release from the capsule in the upper parts of the GI tract was postponed by the 
acidoresistant layer at the capsule surface. To prevent the contact among the outer anionic 
layer and inner cationic (Eudragit E) polymer, an intermediate water soluble layer was 
introduced. After gastric empting both layers dissolve quickly, exposing the cationic layer to 
the intestinal environment. The cationic layer delayed the release till its complete dissolution 
due to the presence of the organic acid in the inner capsule body together with the drug.  
Microgranular system coated with outer layer of enterosolvent Eudragit FS (dissolves at pH 
higher than 6.8) and inner layer composed of combination of pH independent cationic 
polymers Eudragit RL and Eudragit RS demonstrated the potential for delayed release till 
pH 6.5 and sustained release through the colon for approximately 12 hours (Gupta et al., 
2000 as cited in Gupta et al., 2001). Different enzymatically cleavable polymers are also 
reported to be synthesized for application in colonic microflora activated systems.  First 
biodegradable enzymatically cleavable polymers for colon drug targeting are the azo 
polymers composed of hydrophobic and hydrophilic moiety connected by an azo segment. 
Their microbial degradation and consequently drug release rate from the coated drug 
dosage forms depends upon their hydrophilicity. Careful adjustment among the hydrophilic 
and hydrophobic part is a necessity for maintaining gastric resistance and sustained release 
in the lower GI tract. However, reduction of the azo compound is usually very slow which 
might lead to incomplete release of the drug substance.  Major drawback of these 
compounds is coming from the toxicity of the primary aromatic amines resulting from the 
microbial reduction of the more hydrophilic azo compounds and with more hydrophobic 
polymers reduction will be stopped at the hydrazo compounds instead of leading to the 
amines which will influence the drug release rate and mechanism. Azo crosslinked co-
polymers of styrene and hydroxyethylmethacrylate and methyl methacrylate polymers 
crosslinked through bifunctional azo aromatic compounds, azo aromatic group containing 
polyurethanes and pH sensitive terpolymers containing hydroxyethylmethacrylate, methyl 
methacrylate and methacrylic acid were also investigated as sustained release coatings and 
water insoluble hydrogels for colon targeting (Bourgeois, 2005; Leopold, 2001). More 
examples of technologies and combined formulation approaches for pH, time, 
microbiologically and pressure dependent single and multiple unit drug delivery systems 
for colon targeting are presented in Table 2. 
3. Disease oriented strategies for drug targeting in IBD 
During the past fifteen years vast body of research has been done on CD and UC complex 
cascade of immunologically driven interactions by inflammatory substances and cytokines. 
Detailed knowledge of different stages of these pathways (Rivkin, 2009; Rutgeerts et al., 
2004; Van Deventer, 1999; Wong et al., 2008) is very useful for identifying new therapeutic 
targets for IBD therapy as well as clarification of the mechanisms of action of current 
therapeutic agents. Improved understanding of the mechanisms of disease and mechanism 
of action of the active substances at the molecular levels brought new ideas and models for 
rational drug targeting and drug delivery at the site of action (organ, tissue, and cell) at the 
same time reducing the concentration at the non-targeted sites. It has been proven that 
development of rational delivery approaches for old therapeutic agents might improve the 
efficacy, decrease the side effects of the therapy, and even improve therapeutic potential of 
the drug substance.  
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On the other hand, advances in the understanding of the pathophysiology of IBD led to a 
great interest in the evaluation of new therapeutic agents with novel and improved 
therapeutic actions and new therapeutic targets. Biological therapy came about as a 
consequence of improved understanding of the mechanism and pathophysiology of the 
disease and it was the most important addition to the IBD therapy in 50 years.  
Development of sophisticated drug targeting carriers for per oral delivery of new protein 
and peptide therapeutic agents for the treatment of IBD is by no means essential not only to 
provide stability, efficacy and improved targeting at the site of inflammation but to decrease 
the serious side effect of the biological therapeutics when administered through 
conventional parenteral dosage forms. The underlying mechanism of the novel disease 
oriented experimental strategies for drug targeting is based on complete understanding of 
the mechanisms of the disease and drug action. 
In order to cover the basic principles of the disease oriented strategies for GI targeting based 
on micro- and nano-sized carriers and to emphasize the advantages and disadvantages of 
this design approach, short summary of the disease ethyology and pathogenesis will be 
given. Common working hypothesis for explanation and understanding of etiology and 
pathogenesis of IBD is that IBD results from inappropriate and exaggerated mucosal 
immune response of the innate and adaptive immune system to normal constituents of the 
mucosal microflora that is in part determined by the genetic factor. Immunopathogenesis 
results from secretion of toxic peroxide anions, proteases, and oxygen/nitrogen radicals by 
activated macrophages and T-cells that kill the invading bacteria. But, these substances, 
except destroying the antigen, will also cause indiscriminate damage to the surrounding 
tissue. In healthy GI tract the inflammation ceases once the antigen is eliminated and the 
immune cells are no longer directly stimulated. But in IBD the immune cells are stimulated 
from commensal bacteria or GI tract bacterial microflora which is a trigger for continuous 
inflammation, mounting and accumulating inflammatory mediators and inflammatory 
substances with increasing potential for inflammation induced damage to the epithelial 
barrier. Inflammation induced damage will allow increased permeability and infiltration of 
bacteria into the lamina propria causing further stimulation of the immune cells, magnifying 
the inflammatory response and creating a vicious circle of continuous tissue damage. 
Increased permeability of the epithelial barrier, accompanied with increase of M-cell 
number as well as increased uptake activity of the immunoregulatory cells at the site of 
inflammation are the main disease related factors resulting with increased interaction with 
the physical systems like micro- and nano-particles (MPs and NPs) and increased 
concentration of these polymeric carriers loaded with drug substance at the site of action 
(Babbs, 1992; Beckman & Ames, 1997; Cuvelier et al., 1994; Grisham & Granger, 1988; Ina et 
al., 1999; Nikolaus et al., 1998; Oz & Ebersole, 2008; Uguccioni et al., 1999). During 
inflammation the particles will be concentrated in an increased manner in the lamina 
propria and in the follicle region not only through the usual gateway like antigen sampling 
microfold cells (M-cells) overlying the lymphoid follicles of Payer’s patches in the small 
intestines and colonic mucosal lymphoid organs in the colon but  through the leaky 
inflamed epithelium  as well (Fujimura et al., 1992; Van Assche & Rutgeerts, 2002; Yeh et al., 
1998). Further, the interaction of the physical systems with the aberrantly present 
enormously active immunorelated cells (macrophages, dendritic cells) at the site of 
inflammation will increase the concentration of the active substance in the inflammation 
related elements which actually represent therapeutic targets for the anti-inflammatory 
agents.  
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Polymer Design approach Sources  
Eudragit E 100 
Cationic 
copolymer 
soluble in water 
(<pH 5) 
Eudragit L 100  
Anionic 
copolymer 
dissolves at 
pH≥6.0 
Eudragit S 100  
Anyonic 
copolymer 
dissolves at 
pH≥7.0 
Eudragit RL 100 
Eudragit RS 100 
Neutral 
copolymers 
insoluble in water 
with pH 
independent 
swelling 
Eudragit FS 30D 
Anionic 
copolymer 
dissolves at pH 
above 7.0  
CODES™ - colon specific drug delivery technology 
for single unit (tablets) and multiple unit (pellets) 
dosage forms -  developed as a combination of pH, 
time and microbiological approach  
Composition: 
Enteric coating polymer/s (delayed release):  
Eudragit L, HPMCP  
Inner acid soluble coating (sustained release): 
Eudragit E  
Polysacharide containing core  
(Katsuma et 
al., 2004, 
Omar et al., 
2007) 
 
pH dependent reservoir system
pH dependent polymers (delayed release): Eudragit 
L100  and Eudragit S100 
(Khan et al., 
2000)  
Combined pH and time dependent reservoir system
pH dependent polymer (delayed release): Eudragit 
S, Eudragit L  
Time dependent polymers (sustained release): 
Eudragit RL and Eudragit RS 
(Akhgari et 
al., 2006; 
Patel, 2010)  
pH dependent reservoir systems with or without  
disintegrants acting upon the increased 
permeability or dissolution of the acid resistant 
layer  
(Bott et al., 
2004; 
Ibekwe et 
al., 2006; 
Kshirsagar, 
2009)   
 
Ethylcellulose 
Insoluble in water 
pH and time dependent system 
Time dependent polymer matrix: 
ethylcellulose/hydroxyethylcellulose Enterosolvent 
polymer coat: Eudragit S 100 
Time and microbiologically dependent multi-
reservoir drug delivery system 
Time dependent coating was composed of 
ethylcellulose combined with microbiologically 
degradable pectin 
(Alvarez-
Fuentes et 
al., 2004) 
 
 
(Wei et al., 
2008)  
Hydroxypropyl 
methylcellulose 
phthalate 
(HPMCP)  
HP50; HP 55  
Soluble in: water 
(pH>5.0; pH > 
5.5) 
Pressure controlled system: disintegrates due to the 
colon luminal inner pressure composed of HPMCP 
enterosolvent coating over ethylcellulose coating 
pH and microbiologically controlled 
multiparticulated system composed of HPMCP, 
pectin and chitosan   
(Jeong et 
al., 2001)  
 
(Oliveira, 
G.F., 2010) 
 
Table 2. Conventional approaches for colon targeting   
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This phenomenon is equable to epithelial EPR effect (enhanced permeability and retention 
due to increased tumor capillary endothelial permeability) employed for drug targeting in 
solid tumors, as the potential strategy for targeting the inflamed tissue in GI tract is based 
on quite similar principles of increased permeability and retention by the endothelial tissue 
(Lamprecht, 2010; Pastorelli et al., 2008). Compared to conventional GI site targeting using 
pH, time dependent, pressure or microbiologically dependent systems, this approach is a an 
improvement in the principle of accumulation as it targets directly  the site of inflammation. 
The fact that often the exact location of the site of inflammation is not known is not an issue 
for this design approach as drug delivery systems accumulate at the site of inflammation 
due to the increased permeability of the inflamed mucosa as well as particle uptake due to 
the interaction with aberrantly present macrophages and dendritic cells at the site of 
inflammation (Nakase et al., 2000; Tabata et al., 1996). The DDS designed by this targeting 
approach have to be fabricated with specific physicochemical properties and to be able to 
overcome the barriers including steep pH gradient, premature binding to the mucus layer, 
premature uptake or absorption and premature clearance, in order to reach the site of 
inflammation and accumulate according to the epithelial EPR effect in the GI tract.  
 
 
Fig. 1. Translocation of the particles through GI tract epithelium – mechanistic approach (the 
sieving effect and partitioning between mucus/glycocalyx and GI tract epithelium is not 
presented), 1. Un-inflamed mucosa: endocytotic uptake and/or transcytosis through 
enterocytes (particles size<500 nm);  lymphatic uptake - particles adsorbed by M-cells of the 
Peyer's patches (particle size <5 µm) and enhanced adhesion of the MPs and NPs to the 
intestinal epithelium elicited by the adequate muco/bioadhesive coating 2. Inflamed mucosa: 
increased particle uptake due to cytokine induced disruption and leaky epithelium; presence 
of large intercellular pores due to the lower expression of tight junction proteins; improved 
lymphatic uptake due to the increased M-cell population and large population of 
macrophages, dendritic cells and natural killer cells in lamina propria and in the mucus layer. 
Sophisticated manipulation of the physicochemical properties during the fabrication of the 
targeted DDS will provide functionality of the proposed targeting mechanism. Among them 
in addition to particle size and particle size distribution are the stability in GI tract, zeta 
potential, hydrophylicity, hydrophobicity, swelling properties, muco/bioadhesivity, surface 
active groups, density, porosity, etc. 
3.1 Physicochemical properties affecting the efficacy of the DDS 
Targeting IBD using disease oriented strategy requires particle stability and inertness in the 
upper GI tract, increased retention time in the lower parts of the GI  tract, specific interaction 
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of the particles with the inflamed mucosal tissue and immunoregulatory elements as well as 
controlled release at the site of action.  Improved concentration of the DDS and controlled 
release of the drug substance at the site of therapeutic action will contribute to improved 
efficacy as well as decreased systemic exposure and side effects from the therapy. The 
importance and tailoring of the physicochemical properties of the DDS according to selected 
targeting mechanism as well as physiological and patophysiological conditions at the 
therapeutic site of action will be discussed through design, production and physicochemical 
characterization of budesonide loaded chitosan-Ca-alginate MPs intended for targeting and 
treatment of IBD. 
Particle size: Very well known fact about the particle size of the DDS is that accelerated 
elimination and premature clearance due to the diarrhea, a major symptom of IBD, will be 
circumvented by size reduction effect and formulation of MPs or NPs for inflammation 
targeting (Lamprecht et al., 2005; Nakase et al., 2000; Nakase et al., 2001). In order to achieve 
improved localization and prolonged residence time due to increased epithelial 
permeability and enormous immunoregulatory cells activity at the site of inflammation, the 
beads should have an optimal particle size, probably between 4 and 15 µm (Coppi et al., 
2001, 2002;  Lamprecht et al., 2001, 2001a). Carrier systems in that size range are able to 
attach more efficiently to the mucus layer and accumulate in the inflamed region even 
without the need for macrophage uptake. NPs have also shown potential for specific 
accumulation in the areas with inflamed tissue increasing the selectivity of local drug 
delivery. When particles of different sizes are compared one simple conclusion can be 
drawn; that increased retention of particles of all sizes bellow 10 μm is noticed in inflamed 
tissue  and with further size reduction the retention effect is maximized and the clearance 
minimized at the size of approximately 100 nm (Lamprecht et al., 2001, 2001a).   
The mucus gel layer covering the intestinal/colonic mucosa is the first barrier to overcome 
in order to achieve increased localization in the Payer patches, intestinal lymphoid tissue 
and lamina propria. It is well known that UC and, to a lesser extent, CD is associated with 
an alteration and reduction of the protective mucus layer in the large intestine. In active UC 
there was a trend for the mucus layer to become progressively thinner and significantly 
more discontinuous as disease severity increases. The number of goblet cells in UC, which 
synthesize both mucin and intestinal trefoil factor, is reduced in active disease and the gel 
layer is consequently thinner. Mucin quality is also affected by the depletion or decreased 
sulfation and by increased quantity of sialic acid residues (Fujimura et al., 1992; Nakase et 
al., 2001; Yeh et al., 1998). Recently, data developed mainly through the investigation of 
most common UC induced model, dextran sulphate model, were published, pointing that 
the defects in the inner mucus layer may allow massive bacterial penetration into the normal 
sterile crypts and trigger the inflammation. Probably this pathology of the outer and inner 
compact and protective mucus layer contributes to the effect of increased permeability of the 
intestinal mucosa and improved localization of the particulate systems during 
inflammation.  CD, unlike UC, is deep seated, therefore cytokines may initially stimulate 
mucus secretion, and increase thickness, but as the inflammation becomes more extensive it 
might begin to impair mucus production by the epithelium (Dieleman et al., 1998; 
Kojouharoff et al., 1997; Ni et al., 1996).  
Translocation of the particles across the enterocytes/colonocytes and M cells after diffusion 
through mucus/glycocalyx layer as a diffusional and enzymatic barrier for healthy 
intestinal tissue is also affected by size and surface chemistry. Plausible mechanistic 
explanation for size dependent disposition and translocation of MP and NP-DDS in healthy 
www.intechopen.com
 Drug Targeting in IBD Treatment – Existing and New Approaches 
 
313 
GI tract includes the following processes i). endocytotic uptake - particles absorbed by 
intestinal enterocytes through endocytosis (particles size<500 nm); ii). lymphatic uptake - 
particles adsorbed by M cells of the Peyer's patches (particle size <5 μm) and iii). an 
enhanced adhesion of the microparticles and nanoparticles to the intestinal epithelium 
elicited by the adequate muco/bioadhesive coating, resulting, overall in a marked 
improvement of the absorption into the intestinal cells due to the ability of creating 
favorable concentration gradient for absorption or escaping from the multi-drug resistance 
pump proteins. But usually, because of the low endocytic activity of the enterocytes and the 
presence of tight junctions, translocation is mainly performed across the M-cells. 
Macrophages in M-cells invaginate the basolateral membrane to an extent that they come 
very close to the apical membrane, sometimes even protruding into the lumen.  Literature 
data point that further biological fate after internalization depends on the size and chemistry 
as well. It is reported that internalized particles between 2 – 5 μm will remain longer in the 
Payer’s patches, consequently showing very small systemic distribution compared to 
smaller nano sized particles. Particles bellow 2 μm migrated from the patches to mesenteric 
lymph nodes. Altered mucus layer during IBD, leaky epithelium and increased activity of 
the immunoregulatory cells in the inflamed mucosa are additional variables contributing to 
the improved localization of MPs  and NPs at the site of inflammation but at the same time 
they assist the translocation and biological fate of the MP/NP-DDS to be even less 
predictable (Lamprecht, 2010; Nixon et al., 1996; Reece et al., 2001).   
Implementing previously stated targeting principles we have designed microparticulated 
polyelectrolyte muco/bioadhesive DDS for inflammation targeting using the enhanced 
permeability effect as targeting strategy (Crcarevska et al., 2009; Glavas Dodov et al., 2009; 
Mladenovska et al., 2007; Mladenovska et al., 2007; Simonoska Crcarevska et al., 2008).  We 
hypothesized that polyelectrolyte particles with a size from 1-5 μm, narrow particle 
distribution, positive surface charge, pH and crosslinking dependent swelling/bioadhesion 
and release might be suitable DDS for interaction and increased accumulation in the 
inflamed tissue. However, the distribution is not only size related property, but a complex 
interrelationship among size, shape, density, hydrophylicity/ hydrophobicity, swelling 
properties, surface active groups, surface charge of the drug carrier etc. Consequently, only 
complex combination of different attributes of the DDS might result with efficacious 
targeting and performance. 
Surface active groups, zeta potential and muco/bioadhesion: Number of polymers with 
muco/bioadhesive properties are cited in literature. Anionic polymers (polyacrylates and 
cellulose derivatives) and cationic polymers (chitosan) interact with mucus layer through 
non-covalent interactions (hydrophobic interactions, hydrogen binding, van der Waals 
interactions, electrostatic interactions) modulated by pH and ionic strength of the 
environment.  Alginate (anionic polymer) is also citied among polymers with mucoadhesive 
properties involving hydrogen bonding of alginate carboxylic groups with mucus layer as a 
mechanism of mucoadhesive interaction (Chickering, 1995; Deacon et al., 2000; Fiebrig, 1994; 
1995; Gombotz & Wee, 1998; Hejazi & Amiji, 2003; Wittaya-Areekul et al., 2006). Thiolated 
polymers of polyacrylates and cellulose derivatives as well as chitosan thiolated polymers 
exibit cationic covalent bonding building strong covalent disulfide bonds with the cysteine 
domains of mucins (Bernkop-Schnurch et al., 1999).  Other synthetic polymers used in 
bioadhesive formulations are: polyvinyl alcohol, polyamides, polycarbonates, polyalkylene 
glycols, polyvinyl ethers, esters and halides, polymethacrylic acid, polymethyl methacrylic 
acid, methylcellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl 
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methylcellulose, sodium carboxymethylcellulose and various biodegradable polymers like 
poly(lactides), poly(glycolides), poly(lactide-co-glycolides), polycaprolactones, polyalkyl 
cyanoacrylates, polyorthoesters etc.   
Having in mind bio/mucoadhesive properties of natural biopolymers, cationic chitosan and 
anionic alginate were selected for formulation of the budesonide loaded microparticulated 
DDS with a potential for IBD targeting. Sodium alginate LF 10/60 which consists of 65–75% 
of guluronic acid (G) and 25–35% of manuronic acid (M) was used for particle preparation 
because MG types compared with MM and GG types of sodium alginate have better 
flexibility (Smidsrød, 1973), and polymer gels formed from alginate with high percentage of 
guluronic acid (>70%) have highest mechanical strength and stability towards monovalent 
ions (Martinsen, 1991). Chitosan with low viscosity, highly deacetylated was chosen for 
polyelectrolyte complexation with sodium alginate. The fact that the deacetylated chains are 
fully stretched by the electrostatic repulsion among the –NH3+ groups (and the acetylated 
blocks are micelle-like agglomerates because of the hydrophobic forces), leads to a 
conclusion that higher degree of deacetylation might contribute to more efficient process of 
coating. Additional physicochemical stability of the alginate-chitosan polyelectrolyte 
complex was provided by crosslinking with inorganic calcium chloride. The method of 
preparation was simple and highly reproducible one step spray-drying procedure 
(Goracinova, 2005) carried out through concomitant spraying of core (budesonide 
containing alginate solution) and coating solutions (chitosan/calcium chloride solution) 
through adopted two fluid-nozzle. Processes of ionotropic gelation/polyelectrolite 
complexation are simultaneously performed during the short contact of the core and coating 
solution at the tip of the nozzle followed by drying in a spray drying chamber. 
Theoretically, during one-step procedure (Fig. 2.A) both chitosan molecules and calcium 
ions are competing with each other at the same time for the negatively charged groups of 
the alginate molecules and this competition may result in slightly bound chitosan molecules 
at the particle surface,  hence keeping their flexibility when the particles are suspended in 
aqueous milieu. As a result, they are able to interact with the mucin chains and show good 
mucoadhesivity. Zeta potential of the particles is positive and in a magnitude of 30 – 45 mV 
(buffer solutions from pH 2.0 till pH 6.8) providing good stability against agglomeration.  
Considering, that chitosan–Ca–alginate MPs showed a positive value of the zeta potential at 
all pH media an assumption for the presence of chitosan at the surface of the particles can be 
made (Borges et al., 2005).  14C sodium acetate was used for quantitative determination of 
amino groups at the MPs surface and 14C glycine ethyl ester was used for carboxyl  group 
quantification. Although amino groups were prevalent at the surface, also carboxyl groups 
were present at the surface of the carrier. Compared to the one step procedure, when two 
step spray drying procedure was applied for MPs production (preparation of alginate 
particles by spray drying with subsequent crosslinking in a solution of calcium chloride and 
chitosan) particle’s zeta potential was negative, pointing that most of the chitosan amino 
groups are  crosslinked with the carboxyl alginate groups or that the chitosan is deeply 
infiltrated within the pores of the microspheres without forming a continuous coating layer 
at the surface (Fig. 2.B). Surface properties of prepared beads are essential for efficacy of the 
DDS, since positive charge originating from chitosan is crucial for the interaction with 
negatively charged mucus and cell membranes.  During the inflammation these surfaces are 
becoming even more negative due to the increased production of sialic acid and sialic acid 
residues during inflammation (Martinac et al., 2005). Considering the expecting 
performance of the DDS under development and the benefit of increase residence time at 
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the site of inflammation, it is obvious that by utilization of one step spray drying procedure 
expected mucoadhesivity of prepared MPs will be obtained.  
 
 
Fig. 2. Different structural and surface properties of chitosan-Ca-alginate MPs prepared by: 
A. one step spray-drying procedure; B. two step spray-drying procedure 
As crosslinked polyelectrolyte matrices posses different properties compared to the starting 
polymers, physicochemical stability in the bio-environment of the upper GI tract, at the 
same time increased site-specificity and interaction with the bio-environment in the lower 
parts of GI tract (swelling, muco/bioadhession and controlled drug release) were adjusted 
through the degree of crosslinking during the production process. As mucoadhesiveness of 
the polymers and physicochemical stability of the chitosan-Ca-alginate MPs depend on their 
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solubility, flexibility of the polymer backbone and its polar functional groups, it is obvious 
that it can be modified during the cross-linking procedure (Huang et al., 2000; Wittaya-
Areekul et al., 2006). By controlling the degree of crosslinking, through optimization of the 
process conditions, concentration of polymer and calcium chloride solutions, the 
polyelectrolyte bio-matrices were tailored to be inert in the bio-environment of the upper 
parts of GI tract, showing relatively low degree of swelling and high physicochemical 
stability. This slightly swollen matrices travel freely through the GI tract until reaching 
biological fluids with higher pH values and composition which will favor de-crosslinking of 
the matrix, inducing swelling and controlled drug release of the active substance. 
 
 
Fig. 3. Schematic presentation of coating procedure of budesonide loaded chitosan–Ca–
alginate MPs (EMPB) 
Physicochemical changes in the hydrogel environment induce relaxation of the polymer 
network which initiates mucus layer interaction as a result of pH, ion exchange and 
microbiologically induced swelling of the polymer (chitosan enzymatic degradation in 
colon) network. Prolonged residence time of the bioresponsive matrices at the site of action 
will further improve targeting of the inflammation facilitating and improving the contact 
with the mucosal tissue, providing better conditions for particle uptake by the inflamed 
tissue or improved absorption. Increased localization and uptake as well as controlled drug 
release at the site of action will provide significant improvement of the therapeutic efficacy.  
In order to avoid any undesirable erroneous performance in the upper GI tract, the chitosan-
Ca-alginate MPs loaded with budesonide (MPB) were additionally coated with 
enterosolvent polymer (EMPB), as a second control barrier to the drug release at pH range 
from 2.0 to 6.8 (Fig. 3).  
In order to test the suitability of prepared particles for efficient treatment of IBD in vivo, 
studies on rat model of TNBS induced colitis were performed. GI tract time distribution 
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study indicated that complete gastric emptying was reached within 2 hours, while after 6th 
hour most of the MPs were located in the colon where the radioactive material deposits 
remained detectable even after 24 hours. When correlated with GI time distribution studies 
the in vitro swelling behavior, mucoadhesion and in vitro drug release correlated with the 
expected performance in vivo (Fig. 4A, B). 
 
 
Fig. 4. A. GI tract distribution of 99mTc labeled MPs after peroral administration to Wistar 
rats with TNBS induced colitis (mean ± SD, n=12), swelling and mucoadhesive 
properties of EMPB (mean ± SD, n=3). B. In vitro release profiles of BDS suspension, 
MPB and EMPB (2 hours at pH 2.0; additional 4 hours at pH 6.8 and up to 24 hours 
at pH 7.4) (mean ± SD, n=3); Colon/body weight ratio and total score points after the 
treatment with EMPB, MPB, BDS suspension, blank uncoated and Eudragit 
coated MPs ( MP and  EMP), as well as non treated animals sacrificed 6th day 
after colitis induction, (mean ± SD; n=5), ○ statistically significant difference (P<0.05) 
compared to MPB, • statistically significant difference (P<0.05) compared to EMPB.  
C. Photographs and histology of a representative colon specimens of animals with TNBS 
induced colitis: non treated group–severe inflammation with complete destruction of 
mucosa structure followed by loss of epithelium; treated with BDS suspension - focal 
ulcerations, necrosis with demarcation, loss of the necrotic epithelium, and formation  
of granulation tissue; treated with MPB - lower degree of necrosis with distinct 
boundary of necrotic lesions, focal erosive changes, but also, formation of granulation tissue, 
regeneration and parts with normal proliferating mucosa; treated with EMPB - focal 
ulcerative lesions, necrosis with focal character and distinct boundary from the normal 
tissue, lower parts of mucosa with large granulation tissue. Regeneration tendency  
could be observed easily. 
A.
B. C. 
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Efficacy of prepared MPs (selected uncoated and Eudragit coated formulations, 
CaCl2:alginate=1:0.625) was evaluated on male Wistar rats using experimentally TNBS 
induced colitis (Crcarevska et al., 2009). For comparison, adequate blank MPs, as well as 
budesonide (BDS) suspension were used. After 5 days of daily administration by oral 
gavage of prepared formulations, the rats were sacrificed and colon/body weight ratio, 
gross morphological and histological evaluation, and clinical activity score as inflammatory 
indices were determined. Individual clinical and histological evaluation showed that colitis 
severity was suppressed in following order BDS suspension < MPB < EMPB (Fig. 4C). 
Clinical activity score decreased in the same order (Fig. 4B). Statistical analysis of total score 
points indicated that the incorporation of budesonide into MPs showed significant 
differences in favor of efficacy of the DDS with expected accumulation at the site of 
inflammation, mucoadhesive properties and controlled release at the site of action (one-way 
ANOVA, P<0.05) (Crcarevska et al., 2009). Fig. 4B comparatively presents the drug 
dissolution profiles of the tested formulations to the efficacy of designed systems in the 
treatment of TNBS induced colitis.   
It is obvious that the system showing postponed release until colon and controlled release 
during colon residence time or at the site of action demonstrated highest in vivo efficacy. In 
fact this is most likely due to the unique combination of bio/mucoadhesive properties of 
designed system along with physicochemical and biopharmaceutical properties, hence, by 
its design providing improved localization in the inflamed tissue and/or prolonged 
residence time in colon. Namely, carrier system with such properties possess ability to 
attach more efficiently to the mucus layer in the lower GI tract and accumulate in the 
inflamed region even without need for macrophage uptake, although the particles were 
designed to be taken up by macrophages easily as well. The system is inert in the upper GI 
tract, showing minimal adhesion and swelling but, anyway, second line defense was added 
with Eudragit coating in order to prevent any nonspecific adherence in the upper GI tract 
and provide increased drug control release through GI tract. Thus, budesonide is effectively 
delivered in a controlled manner to the colon due to the increased accumulation effect in the 
inflamed tissue of the MPs itself and controlled release at the site of action. Controlled drug 
release allows pharmacological effects to be extended due to the prolonged residence time 
of the carrier system at the targeted inflamed area. In fact, enteric coated MPs are specific 
complex system different from uncoated MPs, by their in vitro and hence in vivo 
performance. Although both systems show improved in vivo efficacy, the Eudragit coated 
one outperformed non coated MPs during the in vivo studies.  
4. Specific colon targeting 
Theoretically, the selectivity of inflammation targeting in GI tract can be improved by 
attachment of various ligands at the surface of the carriers. Specific interactions with the 
receptors uniformly present at large areas or only in a specialized areas in the GI tract will 
improve bioadhesion and absorption, capacity for endocytosis and cell localization. Number 
of ligands and ligand-receptor pairs are discovered and examined for targeting the healthy 
and diseased tissue. Among them are receptor-recognizable ligands, such as lectins, toxins, 
viral haemagglutinins, invasins, transferrin, and vitamins (Vitamin B12, folate, riboflavin 
and biotin), which may improve the specificity of the delivery systems for the target cells 
(Brayden et al., 2005; Clark et al., 1998; De Boer, 2007; Foster & Hirst, 2005; Leamon & Low, 
2001; Lee et al., 2005; Ota et al., 2002; Roth-Walter et al., 2004, 2005; Russell-Jones et al., 1999; 
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Vinogradov et al., 1999). The most exploited ligands for GI targeting are different types of 
lectins due to their specificity for the membrane associated carbohydrate rich material 
mainly composed of olligosacharides conjugated with membrane lipids, proteins or peptide 
glycans. When conjugated to DDS and macromolecular drugs, depending on the lectin 
structure and sugar specificity, lectins may adhere and bind to the cellular surface or induce 
cellular uptake and internalization routing of the DDS. However, there are two distinct 
layers present in the intestinal mucosa, mucus layer and the glycocalix that are reach with 
oligosaccharides. Carbohydrate domains of glycolipids and glycoproteins protrude 
outwards the cell membrane to create, together with the acidic mucopolysaccharides, a thick 
meshwork or glycocalyx. Adhesion of the lectinised DDS at the mucus layer will produce 
effect similar to non-specific mucoadhesives, prolonging the residence time at the site of 
absorption, and dependent on the physicochemical properties of the carrier as well as the 
type and intensity of mucoadhesive interaction increased concentration gradient between 
the lumen and enterocytes and facilitated absorption might be also provided (Gao et al., 
2007; Gupta, 2009; Irache et al., 2008; Smart, 2004). Anyway, this highly viscous mucus layer 
is also a barrier to the diffusion of the DDS towards transmembrane mucin associated 
oligosaccharides into the glycocalyx contributing to low accessibility and low predictability 
of cytoadhesion and/or cytoinvasion with lectin mediated DDS. If the physicochemical 
properties of the carrier (particle size, polymer properties, surface charge, surface active 
groups as well as the nature of attached ligand) promote mucus diffusion, partitioning of 
the formulation to the cell surface is possible due to the reversibility of the lectin-mucin 
interaction, even if the similar oligosaccharides in the mucus layer and glycocalyx are the 
targeted one. Interaction with the specific carbohydrates of the glycocalyx is also possible 
and it will induce cytoadhesion increasing the concentration gradient and improving 
absorption. Apart from this interaction, lectins might interact with carbohydrate domains of 
glycolipids and glycoproteins protruding outwards the cell membrane into the glycocalyx 
(glycosylated cell receptor interaction). Lectins interacting wih the glycocalix of certain 
region or certain cell types in GI tract are so called “bioadhesives of second generation” 
(Lehr, 2000; Tao et al., 2003). Direct adhesion to the cell wall will certainly overcome the 
limitation of mucoadhesion contact time improvement limited to few hours, extending the 
residence time and the interaction time to several days. However, glycocalyx sieve function 
is again important for the receptor accessibility and the interaction with glycosylated 
receptors at the cell membrane which for some lectines as wheat germ agglutinin (WGA) for 
epidermal growth factor (EGF)-receptor might induce receptor mediated endocytosys and 
internalization of nano-scaled carrier systems into acidic endosomal compartments, 
releasing the drug into the cytoplasm or part of the nano-carriers can also follow transcytotic 
patway (Lochner et al., 2003). 
The features of different sites and cell types as well as characteristics of the overlying mucus 
layer and glycocalyx (thickness and glycosylation pattern) are well documented through 
literature. Folicle associated epithelium covering the Payer patches with its M-cells 
specialized in transcytosis; weak mucus production, unique ultrastructure of the glycocalyx 
and glycosylation pattern, number of infiltrated B cells, T cells, macrophages and dendritic 
cells, lack of subepithelial myofibroblast sheat and its basal lamina much more porous 
compared to regular epithelia are characteristics that support different translocation pattern 
and membrane receptor accessibility (Gabor et al., 2004; Gupta, 2009). Also, although M-
cells highly express diverse terminaly glycosylated glycoconjugates which may be exploited 
as receptors, the uptake of particles by M-cells is not entirely dependent on specific ligand 
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binding, since adherence to M-cells by any mechanism leads to endocytosis, phagocytosis, 
pinocytosis, and macropinocytosis or any other mechanism used for the ingestion of the 
extracellular material. Colonic mucosa doesn’t contain Payer’s patches but it contains large 
lymphoid follicles of a dome-type configuration, extended as far as the lamina propria of the 
mucosa and associated with massive lymphoid aggregations spreading beyond the 
muscularis mucosa from the submucosa. The epithelium covering these follicles, is 
associated with a few goblet cells, contains M-cells and many migrating lymphocytes 
crossing through discontinuities of the basal lamina in the vicinity of the M-cells, and is 
specialized, differing from the surrounding mucosa (Fujimura et al., 1992).  
In order to integrate this concepts of glycotargeting into the inflammation targeting the 
influence of mucus production impairment and reduction of the protective mucus layer in 
the intestines during inflammation, increased epithelial permeability, characteristic 
increased immunoregullatory cells activity in the inflamed tissue (section 3), presence of 
occasional erosions for ex. at the apical surface of the colonic lymphoid follicles in a size 
range of 2–6 μm in CD, revealing the naked surface of the dome beneath the epithelium and 
alteration of the glycolation pattern during the inflammation, have to be considered as 
additional factors influencing the  design of the DDS. Additional decoration of the micro- 
and nano-carriers for inflammation targeting designed for increased accumulation due to 
the epithelial EPR effect might further improve the concentration of the active substance in 
the targeted cells due to the effect of cytoadhesion and cytoinvasion. E. coli K99 fimbriae 
adhesin was used to target 6-methyl prednisolone to the inflamed tissue in GI tract of the 
Chron’s patients.  Peptide, protein and DNA therapeutics delivery to the sites of therapeutic 
action will be also possible through the design of these specialized decorated cytoadhesive 
and cytoinvasive nanocarriers (section 5). Targeting the lectine molecules expressed at the 
mammalian cell surface, like galectins which are ǃ-galactoside binding proteins, or direct 
lectine targeting, is also used for normal and diseased colon targeting.   
Alteration of glycolylation pattern is seen during inflammation and neoplastic colonic 
disease. Abnormality in epithelial cell glycoconjugates is commonly present in both UC and 
CD and it may reflect abnormality in mucus glycoprotein synthesis in IBD. As a result 
altered lectin binding by colonic epithelial glycoconjugates in UC and CD can be seen. Up to 
date only limited data are available on the “sugar code” of the GI tract inflammation 
(Gabius, 2000). It is well known that the enterocytes, follicle-associated epithelial cells, M-
cells, immunoregulatory elements and colonocites differ by their glycosylation pattern, but 
the data on the abnormality, differences and characteristics of epithelial glycoconjugates 
during UC and CD are very scarce (Yeh et al., 1998). Even less data can be found about the 
type of interaction mediated by certain oligosaccharide sequence and possible homing of the 
carrier payload into the cell or cell routing triggered by receptor ligand linking.  
Histochemical studies are useful for understanding the altered lectin binding and changes in 
the glycosylation map during cancer and inflammation. In the study of Rhodes et al. high 
proportion of binding of the lectins of peanut agglutinin (PNA), Ulex europeus I (UEAI) and 
Griffonia simplicifolia II (GSII) to UC and CD mucosal samples was shown (Kiss et al., 1997; 
Rhodes et al., 1986, 1988, 2008). It was shown that PNA exhibited specificity for inflamed 
biopsies without binding to the mucosa or free mucus of the normal biopsies.  PNA 
positivity, when present, was most marked in the surface epithelium, particularly in the 
supranuclear region of the epithelial cells. PNA identifies Gal(β1,3)GalNAc which is 
normally obscured by the terminal sialic acid that is added to mucus sialoglycoprotein in the 
Golgi apparatus as the final step in mucin synthesis. The finding of UEAI (fucose binding) 
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positivity in a small proportion of UC and CD rectal biopsies, but not in normal rectal 
mucosa, may be due to reduced sialylation or increased fucosylation. Other lectins used in 
this study like wheat germ agglutinin (WGA), soy bean (SBA), grifonia seed (GSI) showed 
similar affinity to normal, UC and CD biopsies.  
In the study of Melo-Junior et al. (Melo-Junior et al., 2004), it was found that WGA 
presented recognition pattern for diseased tissue. The authors claim that N-
acetylglucosamine was absent or not accessible for lectin recognition in normal tissues, as 
well as mannosides and galactose. L-fucose was found in the intestinal crypts of normal 
glands and UC intestinal biopsies showed intense WGA binding in the gland cells of 
intestinal crypts, indicating high expression of N-acetylglucosamine in these cells in UC. 
Also, fucose binding Lotus tetragonolobus agglutinin was highly bound to UC gland 
epithelium pointing to increased L-fucose levels.   
5. Biological and gene therapies for inflammatory bowel diseases 
Although investigations of IBD pathogenesis did not clear up all misunderstandings of this 
disease and causes of IBD are still unknown, in depth studies of immunopathology of IBD 
and mechanism driving the uncontrolled inflammation enabled the development of design 
strategies for improvement of the efficacy of the conventional therapeutic agents as well as 
identification of new therapeutic targets and novel therapeutic active agents. Genetic factors 
and defects in innate and adaptive immune pathways have been identified, and biological 
therapies that target specific pathophysiological mechanisms of IBD selectively blocking the 
inflammatory mechanisms have been designed.  
The fundamentals of biological treatment strategies involve neutralization of pro-
inflammatory cytokines that plays central role in pathogenesis of CD and UC, use of anti-
inflammatory cytokines and inhibition of neutrophil adhesion or T-cell signaling. Since the 
discovery of the central role of the proinflammatory cytokine TNF α฀in the inflammatory 
cascade of UC and CD, based on large randomized clinical trials, anti-TNF-ǂ agents have 
substantially extended the therapeutic armamentarium in IBD. A variety of biological agents 
have been used to inhibit TNF-ǂ in patients with IBD, including the mouse/human chimeric 
monoclonal antibody (infliximab), the humanized monoclonal antibody CDP571, the human 
soluble TNF-ǂ p55 receptor (onercept), the human monoclonal antibody D2E7 
(adalimumab), the p75 soluble TNF receptor fusion protein (etanercept), and the 
polyethylene glycol (PEG)ylated anti-TNF-ǂ antibody fragment CDP-870. Among these, 
infliximab (formerly cA2) and CDP571 have shown the most promise, particularly in CD. 
However, up to date with few isolated approaches for local administration (Worledge et al., 
2000; AVX-470 in preclinical studies) most of these agents are administered through 
conventional parenteral dosage forms resulting with lower concentration at the site of 
inflammation as well as direct intrusion in the human immune system, number of 
contraindications and serious adverse effects. In addition to these agents that directly 
antagonize and block the activity of TNF-ǂ, alternative pathways for improved therapeutic 
approach are investigated. First of all, gene delivery that will provide sustained production 
of anti-inflammatory proteins has significant promise for local treatment of IBD. Also, 
transcription factors that regulate the synthesis of TNF-ǂ ฀and other proinflammatory 
cytokines are identified like new therapeutic targets. Among them the key transcription 
factor of lymphocytes and macrophages, NF-κB that plays a major role in regulating more 
than hundred proinflammatory cytokines, including  TNF-ǂ,฀is becoming an attractive 
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target for therapeutic intervention in IBD.  A NF-κB decoy therapeutic system using a 
synthetic double stranded oligonucleotide to competitively inhibit binding and interaction 
of NF-κB to their target genoms and prevent the gene induction, transcription and 
production of the proinflammatory cytokines, is already presented in the literature as 
promising therapy for IBD and other inflammatory diseases. Successful intracellular and 
intranuclear delivery of the stable NF-κB decoy to the site of inflammation and action in GI 
tract is a field yet to be explored (Tahara et al., 2011). Finaly, RNA interference therapy 
utilizing short interfering (siRNA), usually composed of 20-25 nucleotides targeted to 
cytosol will trigger gene silencing mechanism through RNA interference where siRNA can 
block the expression of a specific gene (TNF-ǂ ฀or different proinflammatory gene 
expression in IBD) and proinflammatory protein synthesis, thus providing for successful 
therapeutic approach in IBD (Kriegel & Amiji, 2011).  
Gene therapy can be delivered to local sites in GI tract, produce and concentrate a 
therapeutic protein in intestinal tissue, and release negligible amounts into the circulation 
(Kriegel & Amiji, 2011). Examples presented through literature for design approaches for 
gene, peptide and protein targeting in IBD relay on the previous experience with nano- and 
micro-carriers for inflammation and vaccine non specific or specific targeting. Higher 
concentration of the carrier in the inflamed tissue due to enhanced permeability of GI tract 
epithelium as well as increased activity of immune regulatory cells during UC and CD, 
increased residence time and improved carrier/cell non-specific or specific interaction are 
processes assisting the uptake and endosomal release in cytosol or different trafficking 
pathways after triggering internalization. Non-viral nano-sized vectors based on natural 
and/or synthetic polymers for tissue and cell specific delivery with encapsulated DNA, 
siRNA or oligonucleotide payload have shown promising stability, intracellular uptake, 
further trafficking (endosomal/lysosomal escape) and successful transfection efficacy. 
NiMOS (nanoparticles in microspheres system) is based on 200 nm non-condensing type B 
gelatin NPs encapsulated into pH and enzyme attack protective 1-5 μm poly(epsilon-
caprolactone) (PCL) microspheres (Xu et al., 2011). As PCL is degraded by lipases in the 
small and large intestine it is expected that plasmid DNA loaded NPs might be internalized 
by the enterocytes or other cells in GI tract for transfection of the encoded protein. These 
particles loaded with anti-inflammatory murine IL-10 expressing plasmid DNA were 
evaluated for efficacy of transfection, through measurement of the mRNA and anti-
inflammatory protein levels in TNBS induced colitis in Balb/c mice’s. Concomitant effect of 
reduction of pro-inflammatory cytokines and chemokines together with increased 
messenger RNA (mRNA) and antiinflamatory IL-10 levels were reported by the authors 
(Bhavsar & Amiji, 2007). It is well known that successful delivery of siRNAs in the 
cytoplasm, will initiate a process that cleaves the complementary mRNA to prevent its 
processing and translation, blocking the expression of a specific gene eg. those expressed in 
a disease (Plevy & Targan, 2011). NiMOS was also used for oral TNF-ǂ specific siRNA 
delivery (Kriegel & Amiji, 2011) and the system was evaluated for the efficacy of oral TNF-ǂ 
gene silencing using Balb/c mice’s TNBS induced colitis model. It was pointed that the 
system is promising and that lower expression of TNF-ǂ due to silencing preceded the 
downregulation of other inflammatory cytokines and within time showed similar effect on 
the chemokine production. The concept of gene therapy for oral delivery and treatment of 
IBD has received significant attention, while the GI tract offers an ideal target due to large 
surface area and access to the luminal site of inflammation after oral administration. As the 
research in this field is growing day by day successful local gene delivery will probably 
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offer tailor made control of immune responses and inflammatory reactions for an individual 
patient, contributing to the overall success of the anti-inflammatory therapy during IBD.  
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